Introduction
Von Bertalanffy said, "For defining a socalled disease entity a triad of criteria is necessary: a specific etiology, a specific syndrome of symptoms and a specific course. In the light of the criteria mentioned, apparently schizophrenia does not qualify as a disease entity. Its etiology is unknown; its symptomatology offers a large spectrum of alterations from the normal; and no spe cific course or therapy is known." (5) If we accept the basic concept that schizo phrenia is the clinical manifestation of dif ferent pathologies, searching for a unified biochemical explanation for every type of schizophrenia would be illogical. Scientists working on this problem have published many interesting and encouraging papers. Others attempting to replicate previous find ings have become discouraged upon obtain ing inconsistent results.
Today we realize that schizophrenia is not an entity and thus might be due to differing pathologies together with differing biochemical abnormalities, but unfortunate ly as yet there are no methods which provide biochemical differentiation. We are still at the data-collecting stage in the biochemistry of schizophrenia. Every schizophrenic pa tient has to be observed closely wherever this is possible and the result of the bio chemical investigations recorded. During this period, if some unusual results are re corded and observed repeatedly they should be investigated. Eventually these observances will tend to divide schizophrenics into various subgroups. The clinical syndrome now known as schizophrenia will most likely separate into a number of different diseases in much the same way as the 'jaundice' of eighteenth century medicine became a variety of diseases.
We were lucky enough to recognize the so-called eye-skin syndrome (26) and we further investigated this observation. Our findings stimulated us to continue research. Diffuse melanosis was found both in treated and in untreated schizophrenic patients (27) ; the significance of this diffuse pig ment deposit had been investigated but no final explanation found. We explored the formation of the pigment and analyzed its biophysical role (28) . As yet our results do not give the key to the classification of schizophrenia. However, they are encourag ing and offer a logical working hypothesis in some areas of the schizophrenic process.
A. Eye -Skin Syndrome
Between 1959 and 1963 a number of patients at Riverview Hospital, Essondale, B. C. who had been receiving large doses of chlorpromazine developed a peculiar pig mentation of exposed skin areas. This pig mentation was very marked in twenty-one patients and less so in another forty-nine. Of the twenty-one markedly affected pa tients, twelve were noted to have grossly visible corneal and lens opacities. All these patients were female Caucasians, 80 per cent of whom were amenorrheic from the onset of their mental illness. Their ages ranged from 25 to 62 years, the average age being 43. All the affected patients had been receiv ing chlorpromazine (Cpz.) for a minimum of three years prior to the onset of the skin discolouration; their doses averaged from 500 mg. to 1500 mg. daily. Most of these patients were also receiving other tran quillizers (26) . SKIN MANIFESTATIONS. Pigmenta tion of the skin was found only on exposed areas and was most marked on the face, appearing in a 'butterfly' distribution. Other noticeably marked areas included the ex tensor surface of the arms, the forearms, the hands and the back of the legs. In many cases it was visible in the nailbeds, though it was not evident on the palms nor was it ever found in the mucous membranes. In a three-year period some ten thousand patients were examined; of these, seventy showed some discolouration -an occurrence rate of less than 1 per cent. On the face the discolouration varied from a mild diffuse violaceous colour on the cheeks and on the nose, to a deep purplish-grey, metallic colour over the entire face. This discolouration often became apparent first in the summer but did not disappear during the winter months, nor did it fade significantly during the first six months after discontinuing drug treatment. No associated blistering of the skin was noted nor were any texture changes discovered.
Skin biopsies were done on several of the patients showing skin discolouration, sam ples being taken from both pigmented and non-pigmented areas. Further biopsies were then done on patients who were on pro longed high doses of Cpz. but had so far shown no discolouration.
In the affected skin areas the most pro nounced microscopic finding was the pre sence of a marked accumulation of goldenbrown, fine, granular pigment in the macro phages situated around the capillaries in the superficial layers of the dermis. The epider mis itself seemed unremarkable except for an occasional suggestion of absence of the normal melanin in the basal layers of the epidermis. The melanocytes in the skin were DOPA positive. No inflammatory reaction was noted. In the affected patients, biopsies from clinically unaffected sites were similar to those just described but not to the same degree. The histochemistry of the pigment will be described in detail later.
After our observations were published we became aware that there were already two papers published dealing with facial dis colouration in patients treated with pheno thiazine. In 1957, Saunders (61) observed a female patient who developed a dermatitis while on Cpz. and upon histologic examina tion increased melanin-like pigment was re vealed. However, Saunders did not specify whether the pigment was in the epidermis or in the dermis. In 1962 Perrot and Bourjala (52) reported that some patients on phenothiazine medication had developed a metallic bluish discolouration on the facevisage mauve and teinte cuivree. They hypo thesized that this was a toxic reaction; pig ment was never mentioned and no follow-up was made.
Immediately after our publication, Zelickson and Zeller (74) reported their observa tion regarding the skin manifestations of Cpz. treated patients. They studied the af fected areas with electron microscopy (75) and found dense osmiophilic granules in the skin of patients presenting with this syn drome. However, these were in no way similar to melanin granules. Zelickson con cluded in 1965 that these granules were not pure melanin themselves nor wholly deposits of the drug but a combination of the two.
In 1964 Perry et al. (53) studied the skin of one of our patients; they extracted the Cpz. metabolites and analyzed the extracted material, and suggested that this was 7hydroxychlorpromazine or a metabolite of this compound and that this material was deposited in the pigmented skin in addition to melanin or pseudomelanin.
Besides the above mentioned papers sev eral other reports have been published show ing similar results and the general consensus has been that discolouration is the result of a melanin or melanin-like substance in the dermal area (2, 3, 4, 10, 12, 19, 33, 35, 43, 60).
The pathological changes occurring in the skin have been shown by biopsy to consist of clumps of pigment with the staining characteristics of melanin clustered around the blood vessels in the dermis. Electronmicroscopical reports are conflicting. One author (34) found typical appearances of melanin in the skin with some additional osmiophilic particles in the endothelial cells of the blood vessels in the dermis, while another author (76) found no natural melanin in the dermis. OCULAR MANIFESTATIONS. In twelve of the severely pigmented twentyone cases there was a peculiar hazy-brown pigmentation of the exposed sclera and cornea as well as a small central lens opa city. On ophthalmoscopic examination the lens opacity appeared as a dark brown, ir regular stellate opacity with a dense central area and radiating branches. No fundal changes were found. Pigmentation was seen also in the bulbar conjunctiva in the palpe bral fissure. Slit lamp examination revealed the corneal lesion to be stromal in situation and to consist of yellowish-white granules mainly in the posterior half of the cornea but less densely concentrated in the peri pheral cornea than in the centre. The lens opacity consisted of yellow-white dots con centrated at the centre and having radiating arms situated in the anterior subcapsular pole (26) . Following our publication con taining information on ocular changes, inter est in this manifestation increased rapidly. Many papers followed from the United States, England, Australia and France (11, 16, 17, 18, 47, 48, 64, 69). All these obser vations were identical with ours but they gave more detail regarding the pigment de posit and tried to correlate the dose of phenothiazine with the appearance of ocular manifestations.
The general opinion nowadays is that in the eye the lens, the cornea and the con junctiva are usually affected but the retina rarely shows any change. The first changes usually occur in the lens. The early lens and corneal changes may be visible only with the slit lamp; later they can be seen with an ophthalmoscope or even with the unaided eye. Whilst no fundal changes were found in most of the surveys carried out, a few cases have been reported with clustering of pigment at the periphery of the retina. In most surveys no visual defects were found. The frequency of eye changes varies from 30 per cent to 70 per cent in different sur veys.
The ocular changes seem to be clearly related to the amount of drug given and also to the daily dose. Some investigators believe that side effects are not common if the daily dose is small. At first it was supposed that only Cpz. could induce these eye changes until Edler (18) reported similar eye patho logy in five of seventy-four patients who had never had this drug but were on other phenothiazines.
The eye-skin syndrome was observed in schizophrenic patients who had been treated with Cpz. for a prolonged period of time and who had been on fairly high dosages. However, the discolouration in the faces, hands and feet of schizophrenics was ob served and described long before pheno thiazines were in use. In 1912 Cornell (15) considered a cyanotic, metallic bluish discolouration of exposed skin areas in dementia praecox to be pathognomonic of this illness. Bleuler (6) described the same in 1920. MacKenzie Shattock (63) in 1950 described similar pigmentation in female schizophrenics but this pigmentation had never been observed in male psychotics. In Shattock's very detailed analysis of his cases pigmentation of the mucous membranes was never seen and there was a strict cor relation between the patients' psychotic condition and the pigmentation. The eye manifestations had not been observed before chlorpromazine was used.
Changing the medication or discontinuing the phenothiazine therapy does not seem to affect the eye manifestations. However, with the skin discolouration it is different; this changes only if the patient is off the medica tion for at least two years or if his condition improves. We checked up on three patients, all of whom were medium dark, who had escaped from our hospital and were out for more than two years, and on their return their colour was practically normal (29) .
It seems to us that the pathogenesis of eye and skin manifestations is not quite identical. The eye changes are very likely due to the drug; they correlate with the dose and they had also never been observed before Cpz. therapy started. Our long-term observations showed that corneal opacities might improve considerably, although over a period of seven years we never saw much change in the lenticular deposits (stellate shaped opacities). Prien and Cole (55) ob served similar eye changes in schizophrenic patients regardless of whether they were on high or low doses of chlorpromazine, on a placebo or on treatment with some other material. However, they found an eye change of 35 per cent in the high-dose group; in the low-dose group a change of 12 per cent was noted whilst those on a placebo showed an 8 per cent change; and in the routine treatment group only 5 per cent of the patients showed any change. At nine months after conclusion of their study approximately 50 per cent of the corneal opacities had improved greatly or disappear ed completely. The eye deposit might be due to direct light effect polymerizing Cpz. metabolites in the cornea and in the lens. The skin discolouration is only partially in duced by the medication; it was observed before this therapy was started and it is reversible. The patient's illness or the serious ness of his illness might have a role in its genesis. This aspect of these manifestations seems logical to us in the light of our work ing hypothesis which will be described later.
McDonald et al. (44, 45) administered large doses of Cpz. (40 mg./day) to albino, red and black guinea pigs in an attempt to reproduce the abnormal oculocutaneous pig mentation reported in the human subject.
After giving the drug for a period of twelve months and exposing the shaved animals continuously to ultraviolet light, no dermal deposits of pigment were shown. Following the drug treatment slit lamp examination of the guinea pigs' eyes revealed lens opacities in all the animals. Lens opacities had been consistently identified earlier in the female guinea pigs. These interesting experimental findings supported our hypothesis that the eye and skin manifestations are not identical in their genesis.
B. Diffuse Melanosis
Having observed melanin-like pigment in the eye and in certain areas of the dermis of schizophrenic patients on Cpz. therapy we resolved to follow these patients closely. During this period five of these patients died unexpectedly. We assumed that there might be pigment deposits in their internal organs similar to those shown in their skin and eyes. A detailed autopsy and histological examination were done on these patients. Melanin-like pigment was present through out the reticulo-endothelial system, in the parenchymal cells of the internal organs, in the endocrine organs, the heart, the lungs and in the perivascular spaces of the brain (13, 30). The sudden death of these patients drew our attention to similar cases where death was sudden and unexpected although no facial discolouration had been present. Re-examination of autopsy tissues from seven of the latter cases histologically re vealed similar pigment deposits in identical areas.
These two groups of patients had similar pigment deposits in their eyes and internal organs; they had been diagnosed as schizo phrenics and all of them had been on chlor promazine for a long time. It was natural for us to try to correlate generalized mela nosis with phenothiazine therapy or with the schizophrenia process or with both. To check this aspect necropsy material was re examined from between the years 1947-49 when phenothiazines had not been in use. Autopsy material from some fifty schizo phrenics was re-examined and the previously described pigment was found in the same distribution but in lesser amounts. Necrop sy material from some twenty-five nonschizophrenic patients was also examined and similar pigment was found in very small amounts. In most cases the difference be tween the schizophrenic and non-schizo phrenic was prominent. Our conclusion was that in some forms of schizophrenia there is abnormal pigment production, causing the pigment to be deposited in the eyes, the skin and the internal organs, and this abnormal pigment formation is further intensified by the phenothiazine medication.
With all these observations the following questions were raised: a) What is the nature of this pigment? b) Where is it produced?
c) How does it affect the bodily function? d) If it affects the bodily function should it be prevented? e) Is it related to some form of schizo phrenia?
WHAT IS THE NATURE OF THIS PIGMENT? Histochemically the pigment is a golden brown colour and has a fine granular appearance when stained by hematoxylineosin. It proved to be DOPA positive in the skin and DOPA negative in the internal organs tested (liver, lung, kid ney, brain). It does not stain for iron by Gomori's method, nor for bile by Stein's iodine method, nor for lipid by Sudan IV. It does not polarize light and does not fluoresce in the wave length for phenothia zine. Fontana's method of staining for melanin is positive and it could always be bleached by H 2 0 2 in less than twelve hours. With Nile blue sulfate it stains dark green, and with Nile blue sulfate followed by ace tone extraction it remains dark green. With acid-fast stain it is negative.
As can be seen the pigment we found in many schizophrenics had all the histochemical characteristics of melanin. Although none of these methods was specific for melanin we accepted these deposits as melanin until otherwise proven.
The possibility of the pigment being a phenothiazine metabolite was considered. The fact that necropsy material from 1947-49 also contained this pigment showed that most of it could not be a phenothiazine metabolite although part of it might be. If this was so it must be a polymerization mole cule having the same histochemical charac teristics as melanin.
To analyze the pigment further, pigmentcontaining tissues were investigated by elec tron spin resonance (ESR) and examined by electron microscopy (28).
It has been known since 1954 that natural and synthetic melanin have an ESR signal which has been attributed to trapped free radicals in the pigment (7, 14, 24, 73). Skin, liver and thyroid tissues were examined by us in a liquid nitrogen temperature. An E3 Varien ESR spectrometer was used. The signals -width and shape -were identical with the signal of synthetic melanin and of frog skin melanin. We concluded that we were dealing with signals the origin of which was very likely melanin.
Skin, liver and thyroid biopsy material taken from treated, dark patients and from non-treated, normal-coloured patients was examined by electron microscopy. All the materials examined contained fairly high amounts of electron-dense bodies which were thought to be melanin (36, 62).
Although it is known that there is no special test for melanin, results from these different experiments show evidence that the dark pigment is likely to be melanin. By definition melanin is a non-chemical term describing the black or brownish pigment of biological origin, which has been con sidered to be a nitrogen-containing polymer (7) . Melanins have also been defined as natural pigments occurring in living or ganisms at all levels of evolution (49, 50). So melanin is a macro-molecule which is built up (as far as we know from the re search of Nicolaus and his group) from eleven or twelve molecules (adrenochrome might be present if adrenaline is transformed to melanin). These building blocks of melanin are ubiquitous in the living body, so that melanin can be produced in practi cally every organ and cell. Even some phenothiazine metabolites can be trans formed to indolquinones and polymerization of phenothiazine metabolites is real, but according to the definition, melanin is a non-chemical term and all macro-molecules which have certain physical and chemical characteristics are called melanin regardless of the original monomers from which they were formed. WHERE IS IT PRODUCED? Melano cytes in skin biopsies taken from schizo phrenic patients on phenothiazines show a high rate of activity and the DOPA reaction is strongly positive. The skin win dow method shows a large number of cells with melanin in their cytoplasm. From these findings it was assumed that in schizophrenic patients on phenothiazine, melanin was pro duced in the melanocytes of the epidermis at a higher than normal rate. Furthermore, the pigment was deposited in the dermis and picked up by the macrophages and the monocytes and carried away by the blood stream and deposited in the reticuloendo thelial system and in the parenchyma of the internal organs (68). In order to recheck this assumption the blood of twenty schizo phrenics was tested with the buffy coat technique, and to our surprise we were un able to find any pigment-containing cells in eighteen patients, whilst in the two remain ing cases there was only one visible pigmentcontaining cell in each. All cases checked had been diagnosed as schizophrenics, they had a bluish discolouration of the face and they had been on high doses of chlorpro mazine for a lengthy period. In every case the buffy coat of blood was used and at least ten slides were examined. These slides were stained with the Wright-Giemsa meth od. From these findings the idea that melanin could be produced in high amounts in the skin and transported into the internal organs seemed unlikely. The possibility of melanin formation in situ in different organs was entertained and some observations show ed that this assumption might be possible. Firstly, there is no correlation between the discolouration of the skin and the pigment deposit in the liver or thyroid. We examined biopsied liver and thyroid tissues from normal-coloured patients and their organs contained large amounts of pigment. Se condly, with histochemical methods the skin and meningeal slides stained identically with the melanoma which was used as a control. However, the internal organs, liver, lung and thyroid were different, especially when the Fontana method and bleaching were used. It is well known that in vitiligo there is no melanin in the skin whilst the brain melanin is intact (21, 22) . The melanin in the skin is tyrosine melanin but that in the brain is supposed to be catecho lamine melanin (20) . If this is correct the pigment found in our patients' internal organs could differ in its origins -the building blocks of melanin are ubiquitious.
HOW DOES IT AFFECT THE BODILY FUNCTION? The large amount of pig ment deposit in the functional cells of practically every organ raised the question of how it affected the function of the cell.
In 1963 Helmy and Hack (37) histochemically and metabolically investigated the structure and function of the liver of the amphibian, Amphiuma Means. The liver of this amphibian contains dark pigment which has been thought to be melanin. At this time it was known that melanin can under go reversible oxidation-reduction, and it is a strong electron acceptor and donor. This investigation showed that the Amphiuma liver contained melano-protein. These granules are believed to act as a self-con tained oxidation-reduction system. Various histochemical techniques demonstrated an exceedingly low level of mitochondrial activity in Amphiuma liver. Lastly, the gly cogen from the liver was very slowly depleted by fasting, epinephrine and glu cagon -a contrast with the case of glyco gen depletion in the rat. Helmy and Hack's conclusion suggested that there was a funda mental difference between the metabolism of pigment-containing Amphiuma liver and the pigmentless rat liver. These observations stimulated us to investigate further the thyroid and the liver function of pigmented and non-pigmented patients, since these two organs are usually heavily loaded with pig ment granules in schizophrenics. For thyroid function the tyrosine loading test was used (59) and for the liver function the glucagoninduced hyperglycemia test was used.
The oral tyrosine tolerance test has been described in detail by many investigators; we used the method published by Rivlin et al. (59) . L-tyrosine powder (Grade 1) 50 mg/Kg. was given orally to the patient in the morning and the blood samples were taken prior to the amino acid and then every half hour for three hours. Tyrosine was analyzed by a fluorometric method. Forty treated chronic schizophrenic patients were tested with the following results: Glucagon test: 1 mg. of glucagon was given intravenously in fasting states during a period of three to five minutes. The blood sugar was determined before glucagon was given and also at 30, 60, 90, and 120 minutes after its administration (70 These results are not conclusive; the mean rise value appeared to be mainly at the low level for the accepted normal. No conclusion can be made without more investigation.
Parallel with these investigations the con centration power of the kidney was also tested in the same patients and in patients who showed advanced skin pigmentation. Our observation showed that as the kidney tubules are the areas which contain the high est amount of pigment, their concentration power would be limited first. In most cases the concentration power was narrowed and this could be correlated with the length of illness of the patients. We included no pa tients who had ever shown signs of kidney disease.
IF IT AFFECTS BODILY FUNCTION SHOULD IT BE PREVENTED? The frequency of the eye (about 30 per cent) and of the skin manifestations (less than 1 per cent) and the diffuse melanosis observed in schizophrenic patients surprised every
body working in this field. The general feel ing was that pigmentation was detrimental to the patient's appearance; that it might cause visual impairment; and that the func tions of the internal organs could be im paired by such deposits of pigment. The general opinion was that abnormal pigment production should be prevented. Our first cases had all been on Cpz. therapy. This drug was blamed for the pigmentation and the medication was changed or, in cases where it was possible, it was discontinued. All patients were observed closely and for the next six months no changes were noticed in their condition. We should men tion here that the most pigmented patients were the most psychotic ones; consequently it was very difficult to control their condi tion with small doses of phenothiazines, and in some cases it was impossible. Treatment was needed and it was therefore necessary to find other means of prevention rather than just changing their medication.
Our assumption was, and still is, that most of the pigment is melanin. Potts proved that the drug deposit was pigment-dependent, and drug metabolites could be found only where pigment was a priori present. It seem ed logical to interfere with the pigment pro duction and try to block it. The basic idea was that if pigment formation could be blocked efficiently the pigment already pre sent would be excreted and little or no new pigment would be produced and deposited in the skin, the eyes and the internal organs. Following this, since the drug deposit is pigment-dependent, less drug would be de posited in the above named organs.
The classical concept of melanin synthesis is that of Raper (57) and Mason (42). Their concept of melanin biosynthesis involves a series of stepwise oxidations and reductions
leading to 5, 6-indolquinone, which was assumed to undergo condensation and form the polymer. This process starts from tyro-sine, and the presence of oxygen and tyro sinase is needed, tyrosinase being a copper enzyme. During 1962 Nicolaus and his group published their studies of melanin biosynthesis. They cited evidence that as many as ten different substituted indolquinones could be involved as monomers. Fur thermore, Blois (7) recently proposed that melanin biosynthesis probably involves free radical polymerization, producing a highly random three-dimensional polymer in which the number of possible structures is very large. Blois concluded that there are pro bably no two molecules of melanin exactly alike. Nicolaus (50) classified biosynthesized melanins in two large groupstyrosine melanins which are enzyme-depend ent and catechol melanins, with respect to insolubility, chemical inertness, infrared ab sorption and having an electron spin re sonance. Blois concluded that this molecule is a member of the class of random irregular polymers, as are the melanins.
The production line of melanin is con trolled by two groups of factors -the socalled darkening and lightening factors (40). The darkening factors are alpha and beta melanocyte-stimulating hormones (MSH), androgens, estrogens and thyroid extracts.
Lightening factors are epinephrine, norepine phrine, serotonin and melatonin. Pigment will be over-produced when there is an ab solute or relative dominance of darkening factors. As to the relative strength of these factors the following should be noted: if we mark androgen as one unit, the estrogen hormone and the thyroid hormone will be the same or less and the alpha and beta MSH would be one thousand or more. Similarly, the strength in the group of light ening factors would be: epinephrine marked as one unit, norephinephrine and serotonin would be one unit each or less and mela tonin would be one thousand or more.
From the above outlined physiology of the biosynthesis of melanin, the possibilities for a blockage of pigment synthesis are as follows (31).
i) To decrease the needed material for melanin synthesis. From the tyrosine, oxygen and tyrosinase, the simplest way is to inter fere in the tyrosinase function by decreasing the copper intake or increasing the copper output or using both methods. We used dpenicillamine as a copper chelating agent. With this method we expected to decrease the enzyme-dependent melanin production.
ii) To decrease the photo-produced melanin. The photo-produced melanin production is not affected by the method used in i), but it is supposed to be light-dependent and therefore putting the patients in a dark room theoretically has to influence the light dependent melanin formation. This process acts in two ways -directly by electron donation in free radical polymerization and indirectly through the pineal gland by influencing the melatonin cycle. We used this method in only a few cases.
iii) To increase the concentration of the lightening factors. More melanin is produced than normal if there is an absolute or rela tive increase in darkening factors. At this moment we have no knowledge or means to decrease effectively the most effective darkening factors, alpha and beta MSH, and therefore we tried to increase the lightening factors by giving melatonin injections. Once again only a few cases were treated in this way. i) Six middle-aged white female patients were chosen for the first trial, all of whom had a mild to a dark metallic bluish discolouration on the face. Four of them had not been on Cpz. for periods ranging from three to six months yet showed no change in their colour, whilst the two re maining patients were still on this drug. For this trial we used a copper-chelating agent, d-penicillamine, giving doses of 300 mg. three times daily for six days a week. On the seventh day we substituted a mineral supplement; this mineral supplement was designed to replace all the minerals which were lost with the use of penicillamine, with the exception of copper. The diet was a general diet containing approximately 100 g. of proteins, 250 g. of carbohydrates with the remainder fat, making a total in-take of 2,100 to 2,500 calories. During this four-week course of treatment the urinary copper excretion was measured in five of these patients. Measurements had of course been made prior to the commencement of the course and during it.
At the end of the four weeks the colour of four patients was markedly improved, one showed moderate improvement and one was unchanged. By marked improvement is meant that there was a nearly complete dis appearance of the bluish colour, leaving a residual healthy brown tan on the face. Moderate improvement resulted in conver sion of the blue metallic colour of the cheeks to a healthy brown tan, but on the nose and frontal area the metallic blue colour persisted. The four markedly improved pa tients were not on Cpz., whilst the other two patients were on 1,200 mg. daily throughout the trial period (31).
ii) Two middle-aged female patients were put in a dark room for four weeks. Their colour was a deep metallic blue shade and neither of them was on Cpz. Their diet was exactly the same as that mentioned above. The room was illuminated by a dim red light. One patient showed marked im provement with complete disappearance of her metallic blue colour and the other im proved only slightly. Subsequently the se cond patient was put on d-penicillamine and her bluish colour disappeared (31).
iii) In July and August 1966, we tried giving 10 mg. of melatonin daily to six patients. The injection was given at 10 a.m. and the diet followed was the same as that previously mentioned. This trial lasted six weeks but showed no immediate convincing results (32).
Follow-up observations of 36 blue patients.
Thirty-six patients who had been dark or medium blue in 1964 and who had been treated with different psychopharmacologicals were re-examined in 1967 (29) . Three patients were still blue and two of these were continuing to receive Cpz., but the third patient had not received this drug since 1963. The total dose of Cpz. given to these three since 1960 was 2,700 g., 1,500 g., and 1,000 g. respectively.
Fourteen patients are now lightly coloured and showing no bluish tint whatsoever. Four of them, the darkest ones, had been treated with d-penicillamine. The other ten did not receive treatment for melanosis. Eight of these ten are still on doses of 600-1,000 mg. Cpz. daily; the remaining two have had none since 1965.
A further fourteen patients in this group have normal colouring. Six had been treated with penicillamine. The last eight had not had any treatment for their melanosis; (seven had had no Cpz. since 1967 and one is still on this drug).
Of the remaining patients in this group two were discharged and showing normal colouring after d-penicillamine therapy. They are now on 400 mg. of Cpz. daily. The last three patients in the group died of megacolon and pulmonary edema (29) .
Our experiences from the previously des cribed methods and from the follow-up of our thirty-six patients show that a high dose of Cpz. for a prolonged period of time will be likely to induce the eye-skin syndrome and cause melanosis, though not necessarily always. We still have patients on fairly high doses of this drug whose colour is normal.
Our conclusion at this moment is that this drug in high doses is one factor in the induc tion of the melanosis but the presence of other factors seems likely. Other workers got the same impression (67).
Our main purpose in the above trials was to treat or reverse the eye-skin syndrome and to block the abnormal melanin produc tion which was supposed to be a damaging side effect of phenothiazine therapy. From these experiments we found that abnormal melanin production and pigmentation could be successfully reversed by putting the patient in a negative copper balance. A second method of reversing the melanosis might be achieved by putting patients in the dark, since darkness very likely stimulates melatonin formation. Melatonin in amphi bians is a strong lightening factor and this lightening affect of melatonin has been used successfully on vertebrates, for example, While treating bluish-coloured patients, an interesting observation was made by our co-working psychiatrists. Their impression was that patients whose colour improved also improved psychiatrically. This impres sion was shared by several other people and it was therefore decided to check this aspect.
SCHIZOPHRENIA AND COPPER METABOLISM?
This series of experiments was completed in several stages. Firstly, a chelating agent and a normal diet were used, then secondly, a chelating agent and a low copper diet were given in a metabolic unit, and thirdly a chelating agent and a low copper diet were tried in a normal ward set-up. i) D-penicillamine and general diet. Twenty-four chronic schizophrenic male pa tients with ages ranging from 36 to 54 years were chosen. Their previous medication was left unchanged. However, for four weeks half of these men were put on d-penicil lamine (3 x 300 mg/day) and the other half were given a placebo. The results were not conclusive and showed little significant change in the condition of any of the patients.
ii) D-penicillamine and low copper diet in a metabolic unit (51). Ten chronic schizophrenic male patients were chosen, with ages ranging from 23 to 42 years. All were on a diet of low copper intake with less than 1.5 mg. of copper daily. Five patients were treated with a dose of 1,200 mg. of d-penicillamine daily and five were given a placebo. This course lasted for six weeks. The urinary copper excretion was checked before the trial and then three times during the trial period. Serum ceruloplasmin levels were determined during the same period and these were well within the normal range and did not change during the investigation.
The results were assessed by histology from skin biopsies, by the increase of urinary copper excretion, by psychological tests and by psychiatric assessment. In pa tients treated with d-penicillamine and low copper diet the formation of melanin in the skin was inhibited; the urinary copper ex cretion was significantly increased; there was also a remarkable improvement in the symptoms of schizophrenia in these patients.
iii) A trial with d-penicillamine and a low copper diet was conducted in a normal psychiatric ward. Thirty female chronic schizophrenics were chosen, with ages from 35 to 50. A daily diet of less than 1.5 mg. of copper and 1,200 mg. d-penicillamine was given. This was carried out for a period of four weeks. The results were not successful since most of the patients ate, in addition to their low copper diet, regular food from other patients. The copper intake could not therefore be controlled and psychiatric im provement was not noticeable.
All these trials were designed as pilot projects. Even so it seemed to us that some conclusions could be drawn from the results. Penicillamine side effects were never seen. The bluish colouration could be changed with a copper-chelating agent alone, al though a combination of a chelating agent and a low copper diet is more effective. Psychiatric improvement could be seen in some of the schizophrenics when in a nega tive copper balance. The colour change once reversed appeared to last for years, even when the patient went back on Cpz.
C. Chlorpromazine -Melanosis -Schizophrenia
Since the introduction of Cpz. in 1953 it has become one of the most prominent and widely used drugs in psychiatry. Its thera peutic success stimulated intensive research for additional psychopharmaceuticals. With in psychiatric hospitals an attitude of pes simism and despair toward mental illness was replaced by one of hopefulness and confidence, and mental hospitals were trans formed into active treatment centres. Many hospitals discarded the closed ward system in favour of an open-door policy. However, psychopharmaceuticals are potent drugs and world literature contains many reports on their harmful side effects, involving the cardiovascular, endocrine, secretory, dermatologic, renal, hematologic and central nervous systems. Millions of patients around the world have been treated with these drugs. This vast experience testifies that serious complications are very rare indeed and psychiatrists are now learning how to mini mize the risks of pharmacotherapy. Good medical practice requires balancing risk against the good which can be achieved, and the good far outweighs the risk as far as the phenothiazine group is concerned.
After fifteen years in clinical use and discussion in more than 10,000 publications we might ask what we know about the metabolism and biological effect of the chlorpromazine molecule. This line has been extensively investigated by Forrest (23, 25) and by many others in the last few years. Cpz. in vivo might be metabolized by ring oxidation forming free radical intermediates and by side-chain change. Piette (54) postu lated that the free radical intermediates, having extreme stability, are responsible for the psychotropic activity. Blois (8) showed that intraperitoneally administered S35 labeled Cpz. can be localized in tissues con taining melanin. He theorized that there was some form of binding between this drug and some constituent unique to these pig mented tissues; it was later assumed to be the pigment itself. Bolt and Forrest (9) further investigated this binding and con cluded that it is a charge-transfer reaction, Cpz. being the donor and melanin the ac ceptor. Wollemann and Laborit (71) found that injected Cpz. in vivo increases the glucose-6-phosphate dehydrogenase activity in liver and brain, and they concluded that the reason for this effect is that the drug acts as an electron donor. Szent-Gyorgyi (38) and his co-workers investigated the Cpz. molecule from a phy sico-chemical point of view. They found its characteristics exciting because of its unique biological activity. It is the first substance found which has an anti-bonding, highestfilled orbital in its normal stable state. There fore it can be expected to be an exceedingly good electron donor, capable of forming stable charge transfer complexes. Ribo-flavine has similar values but it is unstable and auto-oxidizes rapidly. Pullman (56) achieved the same results from quantummechanical calculations on the electronic structure of phenothiazines. Szent-Gyorgyi (66) after these fascinating findings concluded: "These ideas may be come the starting point of various trains of thought . . . if the symptoms of schizo phrenia can be influenced by electron dona tion, then, perhaps, a lack of electrons may be involved in the genesis of this disease, and if so the question comes up: what has induced it? If the disturbance can be cor rected to some extent by electron donation, could it now have been caused by the presence of an electron acceptor?" I think we have found the answer to Szent-Gyorgyi's question. Melanin is a very strong electron acceptor and is in fact an electron trap mechanism. If this is correct the melanin might induce a lack of electrons and, similar to several other electron accep tors -hyperbilirubinemia in newbornsinhibit oxidative phosphorylation and so damage the brain function. Cpz. as a strong electron donor fills up the spaces of lacking electrons; firstly, in the melanin molecules thereby increasing their amount; secondy, in the functional molecules of the cells, im proving the previously malfunctioning oxi dative phosphorylation (the proper energy production). The electron transport system is very important in cellular energy production, (high energy phosphate bond formation). The electrons drop from a higher energy level to a lower one, cascading downward and releasing energy. This energy is imme diately picked up by ADP and a high energy phosphate bond is produced in the form of ATP; this is one form of cellular energy storage. In the presence of an abnormal electron acceptor such as an electron trap mechanism, this energy flow would be af fected and very likely fewer high energy phosphate bonds formed. The crucial factor in this malfunctioning energy production is the abnormal electron acceptor which in our case is the melanin molecule.
Normally melanin is present in the human body in the skin, the eyes, the meninges and in the basal nuclei in the brain. In many of our schizophrenic patients we found abnormally large deposits of melanin like pigment in the internal organs. The question now is: is this abnormal pigment formation due to the presence of an ab normal increase in the material which is needed in pigment production, or is it due to a failure of the control mechanism?
As has already been mentioned, melanin is a giant molecule polymerized from 10 or 11 building blocks. These monomers are ubiquitous, appearing in every cell. There fore every cell has the ability to polymerize the monomers into a melanin-like giant molecule. Knowing this we might suppose the real problem is in the control mechanism which keeps these monomers in balance or keeps the electron flow, that is, the energy production in balance. Unfortunately this control mechanism is hardly known in humans. In amphibians it is known that the darkening and lightening factors keep the mechanism in balance. But if we put the effective factors of these two groups in pro per perspective, taking into account the fact that we are dealing with schizophrenic pa tients, the lightening factors would seem very important. Catecholamines and sero tonin are the subject of many theories on schizophrenia; the melatonin is produced from serotonin and one of the enzymes needed in this transformation is a special methyltransferase. This transmethylating enzyme is present only in the pineal gland. Therefore it is very vulnerable since it might be metabolically inhibited or congenitally defective. If so, melatonin will not be pro duced or will be produced only partially and instead of melatonin, harmala alkaloid might be manufactured (46) . In this case melanin production will not be controlled and so might be overproduced in the body and harmala alkaloids will be formed in the pineal gland. These alkaloids are hallucino genic and therefore if the methyltransferase in the pineal gland is defective the patient might have diffuse melanosis and might also have hallucinations. Most of our patients showed this clinical picture.
Conclusion
There are many ifs in our theory, but starting from the fact that in many schizo phrenics there is abnormal pigment pro duced and deposited in nearly every organ, it offers a logical working hypothesis. The pineal gland would be the locus of defect and its function will be our prime target for further investigation. This is not new; in fact, the history of research of the pineal gland is a very long one. Herophilos of Alexandria (325-280 B.C.) first mentioned the pineal body function as controlling the 'stream of thoughts'. The same idea was expressed in Descartes' (1596-1650) essays, when he claimed the epiphysis to be the seat of the soul. After the times of Des cartes, interest in the mammalian pineal gland dwindled and it got the reputation of being a rudimentary organ of no great con sequence until the existence of the endo crine organs was realized. At the beginning of this century Marburg was first to pro pagate the theory that the mammalian epi physis would have an endocrine function related to the development of the sexual organs. In 1954 Kitay and Altschule (39) summarized the whole literature relating to the pineal gland. From the anti-serotonin effect of reserpine Woolley (72) assumed that the pineal gland has some role in the causation of certain schizophrenias. Pineal extracts have long been used in the therapy of mental illness, especially in schizophrenia, but with varied results (1). Our work is now centered around the lacking enzyme and the presence of harmala alkaloids.
